SCHEMBL10242941

SCHEMBL10242941

CCNC(=O)c1cccc(-c2ccco2)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.61
KAT6A Q92794 1/20 0.51
CDK8 P49336 1/20 0.49
POLB P06746 3/20 0.49
PRMT6 Q96LA8 1/20 0.48
HPGD P15428 4/20 0.47
ALDH1A1 P00352 3/20 0.47
MAPK1 P28482 2/20 0.47
TSHR P16473 1/20 0.47
RECQL P46063 1/20 0.47
MAPT P10636 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
KDM4E B2RXH2 1/20 0.46
MEN1 O00255 1/20 0.46
ALOX15 P16050 1/20 0.46
CASP1 P29466 1/20 0.46
BLM P54132 1/20 0.46
CASP7 P55210 1/20 0.46
KMT2A Q03164 1/20 0.46
MCL1 Q07820 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10242978 0.89 KEAP1 (0.58) KEAP1KAT6APOLBPRMT6HPGD
SCHEMBL10242939 0.87 SMN1; SMN2 (0.65) KEAP1KAT6APOLBHPGDALDH1A1
SCHEMBL10243027 0.85 SMN1; SMN2 (0.59) KEAP1KAT6APOLBHPGDALDH1A1
SCHEMBL12250927 0.85 KEAP1 (0.57) KEAP1KAT6APOLBPRMT6HPGD
SCHEMBL10242946 0.84 SMN1; SMN2 (0.58) KEAP1POLBHPGDALDH1A1MAPK1
SCHEMBL4439622 0.79 HDAC8 (0.64) KAT6ACDK8HPGDALDH1A1MAPK1
SCHEMBL17777307 0.79 KEAP1 (0.73) KEAP1KAT6APOLBPRMT6ALDH1A1
SCHEMBL1318282 0.78 POLB (0.64) KEAP1POLBPRMT6HPGDALDH1A1
SCHEMBL27605185 0.78 KEAP1 (0.77) KEAP1KAT6APOLBPRMT6ALDH1A1
SCHEMBL10242931 0.78 PRMT6 (0.56) KEAP1POLBPRMT6HPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 KEAP1 3364/4885KAT6A 1476/4885CDK8 4295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.